ArticleThe Journal of clinical investigation2020

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Bianca Balbino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.